Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Food elimination, food substitution, and nutrient supplementation among ARV-exposed HIV-positive persons in southern Ghana.

Laar AK, Lartey MY, Ankomah A, Okyerefo MPK, Ampah EA, Letsa DP, Nortey PA, Kwara A.

J Health Popul Nutr. 2018 Dec 4;37(1):26. doi: 10.1186/s41043-018-0157-x.

2.

A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs.

Daskapan A, Idrus LR, Postma MJ, Wilffert B, Kosterink JGW, Stienstra Y, Touw DJ, Andersen AB, Bekker A, Denti P, Hemanth Kumar AK, Jeremiah K, Kwara A, McIlleron H, Meintjes G, van Oosterhout JJ, Ramachandran G, Rockwood N, Wilkinson RJ, van der Werf TS, Alffenaar JC.

Clin Pharmacokinet. 2018 Nov 8. doi: 10.1007/s40262-018-0716-8. [Epub ahead of print] Review.

3.

Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old.

Kwara A, Yang H, Antwi S, Enimil A, Gillani FS, Dompreh A, Ortsin A, Opoku T, Bosomtwe D, Sarfo A, Wiesner L, Norman J, Alghamdi WA, Langaee T, Peloquin CA, Court MH, Greenblatt DJ.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01657-18. doi: 10.1128/AAC.01657-18. Print 2019 Jan.

4.

Low Birthweight, Retention in HIV Care, and Adherence to ART Among Postpartum Women Living with HIV in Ghana.

Sakyi KS, Lartey MY, Dension JA, Kennedy CE, Mullany LC, Owusu PG, Kwara A, Surkan PJ.

AIDS Behav. 2019 Feb;23(2):433-444. doi: 10.1007/s10461-018-2194-2.

PMID:
29968140
5.

Evaluation of the Adequacy of WHO Revised Dosages of the First-Line Antituberculosis Drugs in Children with Tuberculosis Using Population Pharmacokinetic Modeling and Simulations.

Horita Y, Alsultan A, Kwara A, Antwi S, Enimil A, Ortsin A, Dompreh A, Yang H, Wiesner L, Peloquin CA.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00008-18. doi: 10.1128/AAC.00008-18. Print 2018 Sep.

PMID:
29914960
6.

Zika Virus Exposure in an HIV-Infected Cohort in Ghana.

Sherman KE, Rouster SD, Kong LX, Shata TM, Archampong T, Kwara A, Aliota MT, Blackard JT.

J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):e35-e38. doi: 10.1097/QAI.0000000000001718. No abstract available.

PMID:
29771784
7.

A cross-sectional study of tuberculosis drug resistance among previously treated patients in a tertiary hospital in Accra, Ghana: public health implications of standardized regimens.

Forson A, Kwara A, Kudzawu S, Omari M, Otu J, Gehre F, de Jong B, Antonio M.

BMC Infect Dis. 2018 Apr 2;18(1):149. doi: 10.1186/s12879-018-3053-5.

8.

Human pegivirus (HPgV) infection in Ghanaians co-infected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV).

N'Guessan KF, Boyce C, Kwara A, Archampong TNA, Lartey M, Sagoe KW, Kenu E, Obo-Akwa A, Blackard JT.

Virus Genes. 2018 Jun;54(3):361-367. doi: 10.1007/s11262-018-1555-2. Epub 2018 Mar 17.

PMID:
29551002
9.

Effect of Genetic Variation of NAT2 on Isoniazid and SLCO1B1 and CES2 on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis.

Dompreh A, Tang X, Zhou J, Yang H, Topletz A, Adu Ahwireng E, Antwi S, Enimil A, Langaee T, Peloquin CA, Court MH, Kwara A.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02099-17. doi: 10.1128/AAC.02099-17. Print 2018 Mar.

10.

Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies.

Cao L, Kwara A, Greenblatt DJ.

J Pharm Pharmacol. 2017 Dec;69(12):1762-1772. doi: 10.1111/jphp.12812. Epub 2017 Sep 5.

11.

Causes of death and factors associated with early mortality of HIV-infected adults admitted to Korle-Bu Teaching Hospital.

Saavedra A, Campinha-Bacote N, Hajjar M, Kenu E, Gillani FS, Obo-Akwa A, Lartey M, Kwara A.

Pan Afr Med J. 2017 May 18;27:48. doi: 10.11604/pamj.2017.27.48.8917. eCollection 2017.

12.

Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children.

Yang H, Enimil A, Gillani FS, Antwi S, Dompreh A, Ortsin A, Adu Awhireng E, Owusu M, Wiesner L, Peloquin CA, Kwara A.

Pediatr Infect Dis J. 2018 Jan;37(1):43-51. doi: 10.1097/INF.0000000000001687.

13.

Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes.

Cao L, Greenblatt DJ, Kwara A.

Drug Metab Dispos. 2017 Sep;45(9):1035-1043. doi: 10.1124/dmd.117.076034. Epub 2017 Jun 29.

14.

Use of Non-Prescription Remedies by Ghanaian Human Immunodeficiency Virus-Positive Persons on Antiretroviral Therapy.

Laar AK, Kwara A, Nortey PA, Ankomah AK, Okyerefo MPK, Lartey MY.

Front Public Health. 2017 May 26;5:115. doi: 10.3389/fpubh.2017.00115. eCollection 2017.

15.

Identification and comparative analysis of hepatitis B virus genotype D/E recombinants in Africa.

Boyce CL, Ganova-Raeva L, Archampong TNA, Lartey M, Sagoe KW, Obo-Akwa A, Kenu E, Kwara A, Blackard JT.

Virus Genes. 2017 Aug;53(4):538-547. doi: 10.1007/s11262-017-1469-4. Epub 2017 May 31.

16.

Building Sustainable Local Capacity for Global Health Research in West Africa.

Sam-Agudu NA, Paintsil E, Aliyu MH, Kwara A, Ogunsola F, Afrane YA, Onoka C, Awandare GA, Amponsah G, Cornelius LJ, Mendy G, Sturke R, Ghansah A, Siberry GK, Ezeanolue EE.

Ann Glob Health. 2016 Nov - Dec;82(6):1010-1025. doi: 10.1016/j.aogh.2016.10.011.

PMID:
28314488
17.

ART access-related barriers faced by HIV-positive persons linked to care in southern Ghana: a mixed method study.

Ankomah A, Ganle JK, Lartey MY, Kwara A, Nortey PA, Okyerefo MP, Laar AK.

BMC Infect Dis. 2016 Dec 7;16(1):738.

18.

Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.

Antwi S, Yang H, Enimil A, Sarfo AM, Gillani FS, Ansong D, Dompreh A, Orstin A, Opoku T, Bosomtwe D, Wiesner L, Norman J, Peloquin CA, Kwara A.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01701-16. doi: 10.1128/AAC.01701-16. Print 2017 Feb.

19.

The emerging threat of pre-extensively drug-resistant tuberculosis in West Africa: preparing for large-scale tuberculosis research and drug resistance surveillance.

Gehre F, Otu J, Kendall L, Forson A, Kwara A, Kudzawu S, Kehinde AO, Adebiyi O, Salako K, Baldeh I, Jallow A, Jallow M, Dagnra A, Dissé K, Kadanga EA, Idigbe EO, Onubogu C, Onyejepu N, Gaye-Diallo A, Ba-Diallo A, Rabna P, Mane M, Sanogo M, Diarra B, Dezemon Z, Sanou A, Senghore M, Kwambana-Adams BA, Demba E, Faal-Jawara T, Kumar S, Tientcheu LD, Jallow A, Ceesay S, Adetifa I, Jaye A, Pallen MJ, D'Alessandro U, Kampmann B, Adegbola RA, Mboup S, Corrah T, de Jong BC, Antonio M.

BMC Med. 2016 Nov 3;14(1):160.

20.

HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.

Archampong TN, Boyce CL, Lartey M, Sagoe KW, Obo-Akwa A, Kenu E, Blackard JT, Kwara A.

Antivir Ther. 2017;22(1):13-20. doi: 10.3851/IMP3055. Epub 2016 May 11.

21.

The Role of Nutritional Status on Follow-up among HIV-infected Children at a Teaching Hospital Clinic in Ghana.

Congdon M, Gjelsvik A, Lurie MN, Enimil A, Antwi S, Kwara A.

West Afr J Med. 2015 Jan-Mar;34(1):20-6.

PMID:
26902812
22.

Delayed entry to care by men with HIV infection in Kumasi, Ghana.

Kumar N, Reece R, Norman B, Kwara A, Flanigan T, Rana A.

Pan Afr Med J. 2015 Oct 7;22:107. doi: 10.11604/pamj.2015.22.107.7010. eCollection 2015.

23.

Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients.

Archampong TN, Lartey M, Sagoe KW, Obo-Akwa A, Kenu E, Gillani FS, Yang H, Boamah I, Flanigan T, Kwara A.

BMC Infect Dis. 2016 Jan 13;16:14. doi: 10.1186/s12879-016-1342-4.

24.

Quality of life among Ghanaian adolescents living with perinatally acquired HIV: a mixed methods study.

Enimil A, Nugent N, Amoah C, Norman B, Antwi S, Ocran J, Kwara A, Barker DH.

AIDS Care. 2016;28(4):460-4. doi: 10.1080/09540121.2015.1114997. Epub 2015 Dec 7.

25.

Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.

Brown AN, Drusano GL, Adams JR, Rodriquez JL, Jambunathan K, Baluya DL, Brown DL, Kwara A, Mirsalis JC, Hafner R, Louie A.

MBio. 2015 Nov 3;6(6):e01741-15. doi: 10.1128/mBio.01741-15.

26.

Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection.

Kwara A, Enimil A, Gillani FS, Yang H, Sarfo AM, Dompreh A, Ortsin A, Osei-Tutu L, Kwarteng Owusu S, Wiesner L, Norman J, Kurpewski J, Peloquin CA, Ansong D, Antwi S.

J Pediatric Infect Dis Soc. 2016 Dec;5(4):356-365. Epub 2015 May 26.

27.

Retention in Care of HIV-Positive Postpartum Females in Kumasi, Ghana.

Reece R, Norman B, Kwara A, Flanigan T, Rana A.

J Int Assoc Provid AIDS Care. 2016 Sep;15(5):406-11. doi: 10.1177/2325957415603507. Epub 2015 Aug 28.

28.

Tuberculosis control in RI: maintaining control efforts in the context of declining incidence and funding for tuberculosis programs.

Montague BT, Comella J, Alexander-Scott NE, Bandy U, Kwara A.

R I Med J (2013). 2014 Jan 5;98(1):18-21. No abstract available.

PMID:
25562055
29.

Sex differences in perceived risk and testing experience of HIV in an urban fishing setting in Ghana.

Yawson AE, Appiah LK, Yawson AO, Bonsu G, Aluze-Ele S, Amanhyia NA, Lartey M, Adjei AA, Lawson AL, Beckwith C, Kwara A, Flanigan T.

Int J Equity Health. 2014 Nov 15;13:109. doi: 10.1186/s12939-014-0109-z.

30.

Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.

Court MH, Almutairi FE, Greenblatt DJ, Hazarika S, Sheng H, Klein K, Zanger UM, Bourgea J, Patten CJ, Kwara A.

Antimicrob Agents Chemother. 2014 Jul;58(7):4145-52. doi: 10.1128/AAC.02532-14. Epub 2014 May 12.

31.

Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.

Haas DW, Kwara A, Richardson DM, Baker P, Papageorgiou I, Acosta EP, Morse GD, Court MH.

J Antimicrob Chemother. 2014 Aug;69(8):2175-82. doi: 10.1093/jac/dku110. Epub 2014 Apr 11.

32.

Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance.

Kwara A, Cao L, Yang H, Poethke P, Kurpewski J, Tashima KT, Mahjoub BD, Court MH, Peloquin CA.

Pharmacotherapy. 2014 Mar;34(3):265-71. doi: 10.1002/phar.1388. Epub 2014 Jan 13.

33.

Treatment default among patients initiating HAART at the Korle-Bu Teaching Hospital in Accra, Ghana.

Wilhelm AK, Paci G, Lartey M, Kwara A.

West Afr J Med. 2012 Oct-Dec;31(4):264-9.

PMID:
23468030
34.

Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz.

Carten ML, Kiser JJ, Kwara A, Mawhinney S, Cu-Uvin S.

Infect Dis Obstet Gynecol. 2012;2012:137192. doi: 10.1155/2012/137192. Epub 2012 Feb 28.

35.

Factors associated with recently transmitted Mycobacterium tuberculosis strain MS0006 in Hinds County, Mississippi.

Temple B, Kwara A, Sunesara I, Mena L, Dobbs T, Henderson H, Holcomb M, Webb R.

South Med J. 2011 Dec;104(12):819-26. doi: 10.1097/SMJ.0b013e3182383166.

36.

Factors associated with mortality and default among patients with tuberculosis attending a teaching hospital clinic in Accra, Ghana.

Burton NT, Forson A, Lurie MN, Kudzawu S, Kwarteng E, Kwara A.

Trans R Soc Trop Med Hyg. 2011 Dec;105(12):675-82. doi: 10.1016/j.trstmh.2011.07.017. Epub 2011 Sep 13.

PMID:
21920570
37.

Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers.

Kwara A, Tashima KT, Dumond JB, Poethke P, Kurpewski J, Kashuba AD, Court MH, Greenblatt DJ.

Antimicrob Agents Chemother. 2011 Jul;55(7):3527-33. doi: 10.1128/AAC.00980-10. Epub 2011 Apr 25.

38.

Outcome of hospital admissions in HIV-infected children at the Korle Bu Teaching Hospital, Accra, Ghana.

Kwara A, Shah D, Renner LA.

West Afr J Med. 2010 Nov-Dec;29(6):379-83.

PMID:
21465444
39.

Highly active antiretroviral therapy and employment status in accra, ghana.

Howley I, Lartey M, Machan JT, Talbot EA, Obo-Akwa A, Flanigan TP, Kwara A.

Ghana Med J. 2010 Dec;44(4):144-9.

41.

Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen.

Lartey M, Sagoe KW, Yang H, Kenu E, Xexemeku F, Oliver-Commey J, Boima V, Seshie M, Sagoe A, Mingle JA, Flanigan TP, Wu H, Kwara A.

Clin Infect Dis. 2011 Feb 15;52(4):547-50. doi: 10.1093/cid/ciq196. Epub 2011 Jan 20.

42.

Impact of immigration on the molecular epidemiology of tuberculosis in Rhode Island.

Vanhomwegen J, Kwara A, Martin M, Gillani FS, Fontanet A, Mutungi P, Crellin J, Obaro S, Gosciminski M, Carter EJ, Rastogi N.

J Clin Microbiol. 2011 Mar;49(3):834-44. doi: 10.1128/JCM.01952-10. Epub 2010 Dec 15.

43.
44.

Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.

Kwara A, Ramachandran G, Swaminathan S.

Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):55-68. doi: 10.1517/17425250903393752. Review.

45.

CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.

Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH.

AIDS. 2009 Oct 23;23(16):2101-6. doi: 10.1097/QAD.0b013e3283319908.

46.

Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation.

Kwara A, Lartey M, Boamah I, Rezk NL, Oliver-Commey J, Kenu E, Kashuba AD, Court MH.

J Clin Pharmacol. 2009 Sep;49(9):1079-90. doi: 10.1177/0091270009338482. Epub 2009 Jul 23.

47.

CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.

Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH.

Br J Clin Pharmacol. 2009 Apr;67(4):427-36. doi: 10.1111/j.1365-2125.2009.03368.x.

48.

Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.

Kwara A, Lartey M, Sagoe KW, Xexemeku F, Kenu E, Oliver-Commey J, Boima V, Sagoe A, Boamah I, Greenblatt DJ, Court MH.

J Clin Pharmacol. 2008 Sep;48(9):1032-40. doi: 10.1177/0091270008321790.

49.

Status epilepticus resulting from severe efavirenz toxicity in an HIV-infected patient.

Nijhawan AE, Zachary KC, Kwara A, Venna N.

AIDS Read. 2008 Jul;18(7):386-8, C3.

PMID:
18655316
50.

Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy.

Kwara A, Delong A, Rezk N, Hogan J, Burtwell H, Chapman S, Moreira CC, Kurpewski J, Ingersoll J, Caliendo AM, Kashuba A, Cu-Uvin S.

Clin Infect Dis. 2008 Mar 1;46(5):719-25. doi: 10.1086/527387.

PMID:
18220480

Supplemental Content

Support Center